How to buy Xenetic Biosciences stock | 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Xenetic Biosciences stock in Canada

Own Xenetic Biosciences shares in just a few minutes.

Xenetic Biosciences, Inc is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around $436,942.

How to buy shares in Xenetic Biosciences

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: XBIO in this case.
  5. Research Xenetic Biosciences shares. The platform should provide the latest information available.
  6. Buy your Xenetic Biosciences shares. It's that simple.

Xenetic Biosciences share price

Use our graph to track the performance of XBIO stocks over time.

Xenetic Biosciences shares at a glance

Information last updated 2021-04-16.
Latest market close$N/A
52-week range$0.76 - $3.84
50-day moving average $2.3166
200-day moving average $1.8969
Wall St. target price$5
PE ratio 0.8151
Dividend yield N/A (0%)
Earnings per share (TTM) $-12.323

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
$0 account fee and free ETF transactions.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Wealthsimple Trade
Stocks, ETFs
Deposit and trade $100 and get a $25 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Qtrade Investor
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 ETFs free of charge.
Qtrade Investor offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Scotia iTRADE
Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Xenetic Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Xenetic Biosciences under- or over-valued?

Valuing Xenetic Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xenetic Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xenetic Biosciences's P/E ratio

Xenetic Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Xenetic Biosciences shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Xenetic Biosciences financials

Revenue TTM USD$436,942
Gross profit TTM USD$436,942
Return on assets TTM -16.9%
Return on equity TTM -74.03%
Profit margin 0%
Book value $1.397
Market capitalisation USD$16.4 million

TTM: trailing 12 months

How to short and sell Xenetic Biosciences shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "XBIO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 96,873 Xenetic Biosciences shares held short by investors – that's known as Xenetic Biosciences's "short interest". This figure is 23.1% down from 125,985 last month.

There are a few different ways that this level of interest in shorting Xenetic Biosciences shares can be evaluated.

Xenetic Biosciences's "short interest ratio" (SIR)

Xenetic Biosciences's "short interest ratio" (SIR) is the quantity of Xenetic Biosciences shares currently shorted divided by the average quantity of Xenetic Biosciences shares traded daily (recently around 269091.66666667). Xenetic Biosciences's SIR currently stands at 0.36. In other words for every 100,000 Xenetic Biosciences shares traded daily on the market, roughly 360 shares are currently held short.

However Xenetic Biosciences's short interest can also be evaluated against the total number of Xenetic Biosciences shares, or, against the total number of tradable Xenetic Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenetic Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Xenetic Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0121% of the tradable shares (for every 100,000 tradable Xenetic Biosciences shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xenetic Biosciences.

Find out more about how you can short Xenetic Biosciences stock.

Xenetic Biosciences share dividends

We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Xenetic Biosciences's shares ever split?

Xenetic Biosciences's shares were split on a 1:12 basis on 24 June 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.

Xenetic Biosciences share price volatility

Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $0.76 up to $3.84. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.5262. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Xenetic Biosciences overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site